These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29806885)

  • 1. Evolution of clinical characteristics and outcomes of synthetic cannabinoid receptor agonist exposure in the United States: analysis of National Poison Data System data from 2010 to 2015.
    Cordeiro SK; Daro RC; Seung H; Klein-Schwartz W; Kim HK
    Addiction; 2018 Oct; 113(10):1850-1861. PubMed ID: 29806885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists: a report from the United Kingdom National Poisons Information Service.
    Waugh J; Najafi J; Hawkins L; Hill SL; Eddleston M; Vale JA; Thompson JP; Thomas SH
    Clin Toxicol (Phila); 2016 Jul; 54(6):512-8. PubMed ID: 27091041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of Australian legislative changes on synthetic cannabinoid exposures reported to the New South Wales Poisons Information Centre.
    Cairns R; Brown JA; Gunja N; Buckley NA
    Int J Drug Policy; 2017 May; 43():74-82. PubMed ID: 28343112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of novel psychoactive substance exposures reported to New York City Poison Center, 2011-2014.
    Palamar JJ; Su MK; Hoffman RS
    Am J Drug Alcohol Abuse; 2016; 42(1):39-47. PubMed ID: 26678258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effects of cannabis compared to synthetic cannabinoid receptor agonists (SCRAs): a retrospective cohort study of presentations with acute toxicity to European hospitals between 2013 and 2020.
    Waters ML; Dargan PI; Yates C; Dines AM; Eyer F; Giraudon I; Heyerdahl F; Hovda KE; Liechti ME; Miró Ò; Vallersnes OM; Anseeuw K; Badaras R; Bitel M; Bonnici J; Brvar M; Caganova B; Calýskan F; Ceschi A; Chamoun K; Daveloose L; Galicia M; Gartner B; Gorozia K; Grenc D; Gresnigt FMJ; Hondebrink L; Jürgens G; Konstari J; Kutubidze S; Laubner G; Liakoni E; Liguts V; Lyphout C; McKenna R; Mégarbane B; Moughty A; Nitescu GV; Noseda R; O'Connor N; Paasma R; Ortega Perez J; Perminas M; Persett PS; Põld K; Puchon E; Puiguriguer J; Radenkova-Saeva J; Rulisek J; Samer C; Schmid Y; Scholz I; Stašinskis R; Surkus J; Van den Hengel-Koot I; Vigorita F; Vogt S; Waldman W; Waring WS; Zacharov S; Zellner T; Wood DM
    Clin Toxicol (Phila); 2024 Jun; 62(6):378-384. PubMed ID: 38934347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suspected synthetic cannabinoid receptor agonist intoxication: Does analysis of samples reflect the presence of suspected agents?
    Tebo C; Mazer-Amirshahi M; DeGeorge L; Gelfand B; Leak C; Tolliver S; Sauter D
    Am J Emerg Med; 2019 Oct; 37(10):1846-1849. PubMed ID: 30595429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in hospital presentations following analytically confirmed synthetic cannabinoid receptor agonist exposure before and after implementation of the 2016 UK Psychoactive Substances Act.
    Craft S; Dunn M; Vidler D; Officer J; Blagbrough IS; Pudney CR; Henderson G; Abouzeid A; Dargan PI; Eddleston M; Cooper J; Hill SL; Roper C; Freeman TP; Thomas SHL
    Addiction; 2022 Nov; 117(11):2899-2906. PubMed ID: 35665553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Effects of Synthetic Cannabinoid Receptor Agonists Compared with Marijuana in Emergency Department Patients with Acute Drug Overdose.
    Zaurova M; Hoffman RS; Vlahov D; Manini AF
    J Med Toxicol; 2016 Dec; 12(4):335-340. PubMed ID: 27255136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic Cannabinoid-Related Deaths in England, 2012-2019.
    Yoganathan P; Claridge H; Chester L; Englund A; Kalk NJ; Copeland CS
    Cannabis Cannabinoid Res; 2022 Aug; 7(4):516-525. PubMed ID: 33998886
    [No Abstract]   [Full Text] [Related]  

  • 10. Cannabis and synthetic cannabinoid exposure reported to the Israel poison information center: Examining differences in exposures to medical and recreational compounds.
    Sznitman SR; Pinsky-Talbi L; Salameh M; Moed T; Bentur Y
    Int J Drug Policy; 2020 Mar; 77():102711. PubMed ID: 32126489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic cannabinoid use among a sample of individuals enrolled in community-based recovery programs: Are synthetic cannabinoids actually preferred to other drugs?
    Smith KE; Staton M
    Subst Abus; 2019; 40(2):160-169. PubMed ID: 30457960
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute Toxicity Associated with Use of 5F-Derivations of Synthetic Cannabinoid Receptor Agonists with Analytical Confirmation.
    Abouchedid R; Ho JH; Hudson S; Dines A; Archer JR; Wood DM; Dargan PI
    J Med Toxicol; 2016 Dec; 12(4):396-401. PubMed ID: 27456262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study.
    Hill SL; Najafi J; Dunn M; Acheampong P; Kamour A; Grundlingh J; Blain PG; Thomas SH
    Clin Toxicol (Phila); 2016 Sep; 54(8):638-43. PubMed ID: 27251903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ayahuasca Exposure: Descriptive Analysis of Calls to US Poison Control Centers from 2005 to 2015.
    Heise CW; Brooks DE
    J Med Toxicol; 2017 Sep; 13(3):245-248. PubMed ID: 27896660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of edible marijuana product exposures reported to United States poison centers.
    Cao D; Srisuma S; Bronstein AC; Hoyte CO
    Clin Toxicol (Phila); 2016 Nov; 54(9):840-846. PubMed ID: 27418198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A transnational perspective on the evolution of the synthetic cannabinoid receptor agonists market: Comparing prison and general populations.
    Norman C; Halter S; Haschimi B; Acreman D; Smith J; Krotulski AJ; Mohr ALA; Logan BK; NicDaéid N; Auwärter V; McKenzie C
    Drug Test Anal; 2021 Apr; 13(4):841-852. PubMed ID: 33463894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2011 Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 29th Annual Report.
    Bronstein AC; Spyker DA; Cantilena LR; Rumack BH; Dart RC
    Clin Toxicol (Phila); 2012 Dec; 50(10):911-1164. PubMed ID: 23272763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analytical confirmation of synthetic cannabinoids in a cohort of 179 presentations with acute recreational drug toxicity to an Emergency Department in London, UK in the first half of 2015.
    Abouchedid R; Hudson S; Thurtle N; Yamamoto T; Ho JH; Bailey G; Wood M; Sadones N; Stove CP; Dines A; Archer JRH; Wood DM; Dargan PI
    Clin Toxicol (Phila); 2017 Jun; 55(5):338-345. PubMed ID: 28421836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2014 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 32nd Annual Report.
    Mowry JB; Spyker DA; Brooks DE; McMillan N; Schauben JL
    Clin Toxicol (Phila); 2015; 53(10):962-1147. PubMed ID: 26624241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic cannabinoid exposures reported to Texas poison centers.
    Forrester MB; Kleinschmidt K; Schwarz E; Young A
    J Addict Dis; 2011 Oct; 30(4):351-8. PubMed ID: 22026527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.